variables: 816993
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
816993 | New bacteriologically confirmed pulmonary tuberculosis cases tested for isoniazid and rifampicin resistance | new cases tested for isoniazid and rifampicin resistance | 2023-12-05 11:51:59 | 2024-07-25 22:54:11 | 2017-2022 | 6308 | { "unit": "new cases tested for isoniazid and rifampicin resistance", "numDecimalPlaces": 0 } |
0 | dst_rlt_new | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#dst_rlt_new | 2 | major | Number of new bacteriologically confirmed pulmonary tuberculosis cases tested for isoniazid and rifampicin resistance. Isoniazid and rifampicin are antibiotics used to treat tuberculosis. | Among new pulmonary tuberculosis patients with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicine. | [] |
int | [] |
ab07b7ed51e8e9d4017e18134185c6eb | 375599a2822aa4fd909b5e257dc9d5df |